Online inquiry

IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5459MR)

This product GTTS-WQ5459MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets tcdB gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	WP_003434531.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	57299394
UniProt ID	P18177

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5459MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6373MR	IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	CSL654
GTTS-WQ7392MR	IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	GA101
GTTS-WQ2688MR	IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	AMG 785
GTTS-WQ8078MR	IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	h5G1.1HuG2/G4
GTTS-WQ12480MR	IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	NN-8226
GTTS-WQ14019MR	IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	REGN-3500
GTTS-WQ9248MR	IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	IMMU-107
GTTS-WQ5435MR	IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	CDA 1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST